We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xerox Holdings Corporation (XRX) - free report >>
Marcus Corporation (The) (MCS) - free report >>
Six Flags Entertainment Corporation New (SIX) - free report >>
Image: Bigstock
New Strong Sell Stocks for October 27th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
The Marcus Corporation (MCS - Free Report) owns and operates movie theatres, and hotels and resorts. The Zacks Consensus Estimate for its current year earnings has been revised 6.1% downward over the last 30 days.
Six Flags Entertainment Corporation (SIX - Free Report) owns and operates regional theme and waterparks. The Zacks Consensus Estimate for its current year earnings has been revised 4.7% downward over the last 30 days.
Welltower Inc. (WELL - Free Report) drives transformation of health care infrastructure. The Zacks Consensus Estimate for its current year earnings has been revised 0.6% downward over the last 30 days.
Xerox Holdings Corporation (XRX - Free Report) designs, develops, and sells document management systems and solutions. The Zacks Consensus Estimate for its current year earnings has been revised 12.4% downward over the last 30 days.
Enanta Pharmaceuticals, Inc. (ENTA - Free Report) is a biotechnology company that focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. The Zacks Consensus Estimate for its current year earnings has been revised 1.5% downward over the last 30 days.
View the entire Zacks Rank #5 List.